Agios Pharmaceuticals Inc. (AGIO)
Agios Pharmaceuticals, Inc. (AGIO) Q3 2025 Earnings Call Transcript
Agios Pharmaceuticals, Inc. ( AGIO ) Q3 2025 Earnings Call October 30, 2025 8:00 AM EDT Company Participants Morgan Sanford Brian Goff - CEO & Director Cecilia Jones - Chief Financial Officer Tsveta Milanova - Chief Commercial Officer Sarah Gheuens - Chief Medical Officer and Head of Research & Development Conference Call Participants Eric Schmidt - Cantor Fitzgerald & Co., Research Division Alec Stranahan - BofA Securities, Research Division Marc Frahm - TD Cowen, Research Division Tessa Romero - JPMorgan Chase & Co, Research Division Presentation Operator Good morning, and welcome to Agios Pharmaceuticals Third Quarter 2025 Conference Call. [Operator Instructions] Please be advised that this call is being recorded at Agios' request.
Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Beats Revenue Estimates
Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.78 per share versus the Zacks Consensus Estimate of a loss of $1.93. This compares to earnings of $4.2 per share a year ago.
AGIO Stock Falls as FDA Delays Decision on Pyrukynd for Thalassemia
Agios shares tank as the FDA extends the review period for Pyrukynd in thalassemia by three months, pushing the final ruling to Dec. 7, 2025.
Agios Pharmaceuticals, Inc. (AGIO) Q2 2025 Earnings Call Transcript
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q2 2025 Earnings Call July 31, 2025 8:00 AM ET Company Participants Brian M. Goff - CEO & Director Cecilia Jones - Chief Financial Officer Sarah Gheuens - Chief Medical Officer and Head of Research & Development Tsveta Milanova - Chief Commercial Officer Morgan Sanford - Vice President, Investor Relations Conference Call Participants Andrew Scott Berens - Leerink Partners LLC, Research Division Emily Claudia Bodnar - H.C.
Agios Pharmaceuticals (AGIO) Reports Q2 Loss, Beats Revenue Estimates
Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.93 per share versus the Zacks Consensus Estimate of a loss of $1.74. This compares to a loss of $1.69 per share a year ago.
Agios' Q1 Loss Narrower Than Expected, Revenues Lag Estimates
AGIO's earnings beat estimates in the first quarter of 2025, while revenues miss the same.
Agios Pharmaceuticals, Inc. (AGIO) Q1 2025 Earnings Call Transcript
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q1 2025 Earnings Conference Call May 1, 2025 8:00 AM ET Company Participants Chris Taylor – Vice President-Investor Relations and Corporate Communications Brian Goff – Chief Executive Officer Sarah Gheuens – Chief Medical Officer, Head-Research and Development Tsveta Milanova – Chief Commercial Officer Cecilia Jones – Chief Financial Officer Conference Call Participants Gregory Renza – RBC Capital Markets Alec Stranahan – Bank of America Divya Rao – TD Cowen Hiro Nagayumi – Cantor Emily Bodnar – H.C. Wainwright Tessa Romero – JPMorgan Operator Good morning, and welcome to Agios' First Quarter 2025 Conference Call.
Agios Pharmaceuticals (AGIO) Reports Q1 Loss, Misses Revenue Estimates
Agios Pharmaceuticals (AGIO) came out with a quarterly loss of $1.55 per share versus the Zacks Consensus Estimate of a loss of $1.80. This compares to loss of $1.45 per share a year ago.
Analysts Estimate Agios Pharmaceuticals (AGIO) to Report a Decline in Earnings: What to Look Out for
Agios Pharmaceuticals (AGIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for April 3rd
AGIO, CHGG and EFX have been added to the Zacks Rank #5 (Strong Sell) List on April 3, 2025.
Agios' Q4 Loss Wider Than Expected, Pyrukynd Drives Revenues
AGIO reports mixed fourth-quarter 2024 results. Its sole marketed drug, Pyrukynd, drives revenues year over year.
Agios Pharmaceuticals, Inc. (AGIO) Q4 2024 Earnings Call Transcript
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO ) Q4 2024 Earnings Conference Call February 13, 2025 8:00 AM ET Company Participants Brian Goff - CEO Sarah Gheuens - CMO & Head OF R&D Tsveta Milanova - CCO Cecilia Jones - CFO Chris Taylor - VP, IR & Corporate Communications Conference Call Participants Eric Schmidt - Cantor Fitzgerald Divya Rao - TD Cowen Gregory Renza - RBC Capital Markets Greg Harrison - Scotiabank Chris Raymond - Piper Sandler Alec Stranahan - Bank of America Lydia Erdman - Goldman Sachs Tessa Romero - J.P. Morgan Operator Good morning, and welcome to Agios' fourth quarter 2024 conference call.
